Stockscreener 앱 받기
6.50
6.38%
0.39
시간 외 거래:
6.64
0.14
+2.15%
전일 마감가:
$6.11
열려 있는:
$6.24
하루 거래량:
2.28M
Relative Volume:
1.52
시가총액:
$270.21M
수익:
$317.00K
순이익/손실:
$-53.47M
주가수익비율:
-3.4392
EPS:
-1.89
순현금흐름:
$-49.31M
1주 성능:
+2.20%
1개월 성능:
+9.24%
6개월 성능:
+420.00%
1년 성능:
+171.97%
1일 변동 폭
$6.1259
$6.54
1주일 범위
$6.02
$6.99
52주 변동 폭
$1.10
$10.08
Immuneering Corp Stock (IMRX) Company Profile
명칭
Immuneering Corp
전화
617-500-8080
주소
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
IMRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
6.50 | 386.39M | 317.00K | -53.47M | -49.31M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-13 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2024-03-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-03-15 | 재확인 | Needham | Buy |
| 2024-03-15 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-12-01 | 개시 | Needham | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-04-19 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-04-19 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-03-30 | 개시 | Mizuho | Neutral |
| 2023-02-03 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2022-07-08 | 개시 | Chardan Capital Markets | Buy |
| 2022-04-01 | 개시 | Oppenheimer | Outperform |
| 2022-01-07 | 개시 | Piper Sandler | Overweight |
모두보기
Immuneering Corp 주식(IMRX)의 최신 뉴스
Insider Stock Purchases: October 07, 2025 - Quiver Quantitative
Insider Buying: Immuneering (NASDAQ:IMRX) Director Purchases 7,500 Shares of Stock - MarketBeat
Why Immuneering Corporation stock is in analyst buy zoneEarnings Risk Summary & Growth Focused Stock Reports - newser.com
Will Immuneering Corporation stock outperform Nasdaq indexJuly 2025 Setups & Verified Momentum Stock Watchlist - newser.com
Analyzing recovery setups for Immuneering Corporation investorsMarket Activity Summary & Consistent Profit Focused Trading Strategies - newser.com
What to expect from Immuneering Corporation in the next 30 daysEarnings Performance Report & Free Community Supported Trade Ideas - newser.com
Will Immuneering Corporation stock benefit from commodity prices2025 Retail Activity & Weekly High Return Stock Opportunities - newser.com
Two new option listings and three option delistings on October 2nd - TipRanks
Immuneering Corporation (NASDAQ:IMRX) Receives $17.75 Consensus PT from Analysts - Defense World
Insider Stock Purchases: October 01, 2025 - Quiver Quantitative
Feinberg Peter buys Immuneering Corp (IMRX) shares for $52,730 - Investing.com India
Positive Trial Data Supports 43% Upside for Immuneering Corporation (IMRX) - Insider Monkey
Peter Feinberg Acquires 5,000 Shares of Immuneering (NASDAQ:IMRX) Stock - MarketBeat
Can Immuneering Corporation stock sustain market leadershipEarnings Performance Report & Reliable Breakout Forecasts - newser.com
Will Product Innovation Drive Rajasthan Gases Limited Stock in YEARInstitutional Buying Trends & Create Your Free Watchlist Instantly - earlytimes.in
11 Best Fast Money Stocks to Buy Now - Insider Monkey
Identifying reversal signals in Immuneering Corporation2025 Analyst Calls & Risk Managed Investment Signals - newser.com
Immuneering Corporation (NASDAQ:IMRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Immuneering (NASDAQ:IMRX) Price Target Raised to $20.00 at Chardan Capital - Defense World
Immuneering to host call on pancreatic cancer treatment data By Investing.com - Investing.com Nigeria
Immuneering To Discuss Recently Announced Overall Survival Data From Phase 2A Clinical Trial Of Atebimetinib + Mgnp In First-Line Pancreatic Cancer Patients On September 29 - TradingView
MBX, uniQure among biotechs raising nine-figure sums: Public Equity Report - biocentury.com
Immuneering to host call on pancreatic cancer treatment data - Investing.com
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 - The Manila Times
First-Line Pancreatic Cancer Trial Update: Immuneering to Present Survival Data for Atebimetinib + mGnP - Stock Titan
Immuneering (NASDAQ:IMRX) Price Target Raised to $30.00 at Oppenheimer - Defense World
To vanquish pancreatic at last? Immuneering scores in phase II - BioWorld MedTech
Immuneering Stock Rises 21.7% on Supply Agreement With LLY - MSN
Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst (IMRX) - Seeking Alpha
Mizuho reiterates Outperform rating on Immuneering stock after positive data - Investing.com India
Immuneering Asset Nearly Doubles Overall Survival in Pancreatic Cancer After 9 Months - NewsBreak: Local News & Alerts
IMRX: Oppenheimer Raises Target Price Amidst Outperform Rating | - GuruFocus
Oppenheimer Forecasts Strong Price Appreciation for Immuneering (NASDAQ:IMRX) Stock - MarketBeat
Immuneering Corporation’s Stock Rollercoaster: What’s Next? - StocksToTrade
Immuneering price target raised to $30 from $21 at Oppenheimer - TipRanks
Oppenheimer Maintains Immuneering(IMRX.US) With Buy Rating, Raises Target Price to $30 - 富途牛牛
Immuneering Corporation (IMRX) PT Raised to $30 at Oppenheimer - StreetInsider
Mizuho Reiterates Outperform Rating on Immuneering Corporation (IMRX) - StreetInsider
Why PepGen Shares Are Trading Higher By 112%; Here Are 20 Stocks Moving Premarket - Benzinga
Needham Maintains Immuneering(IMRX.US) With Buy Rating, Maintains Target Price $11 - 富途牛牛
Immuneering Announces $25M Securities Purchase Agreement - TipRanks
Promising Clinical Trial Results and Favorable Safety Profile Support Buy Rating for Immuneering - TipRanks
IMRX Soars On Pancreatic Cancer Data, PEPG Sets DM1 Splicing Correction Record, CLPT On Watch - RTTNews
Immuneering Reveals Pricing Of 18.96 Mln Shares Public Offering At $9.23/Shr - Nasdaq
Immuneering Corp (IMRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.05%
4.71%
자본화:
|
볼륨(24시간):